Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have received an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, four have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $90.6667.

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of Tarsus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. HC Wainwright restated a “buy” rating and set a $88.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Monday, May 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Oppenheimer started coverage on shares of Tarsus Pharmaceuticals in a research report on Friday, April 24th. They set an “outperform” rating and a $98.00 price objective on the stock.

Tarsus Pharmaceuticals Stock Up 0.6%

Shares of TARS stock opened at $59.64 on Tuesday. The company has a market capitalization of $2.57 billion, a price-to-earnings ratio of -52.32 and a beta of 0.49. Tarsus Pharmaceuticals has a one year low of $38.51 and a one year high of $85.25. The company’s fifty day moving average price is $64.49 and its 200-day moving average price is $70.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.71.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.24. The firm had revenue of $162.05 million for the quarter, compared to the consensus estimate of $149.60 million. Tarsus Pharmaceuticals had a negative net margin of 9.02% and a negative return on equity of 14.19%. Sell-side analysts expect that Tarsus Pharmaceuticals will post -0.59 EPS for the current fiscal year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, insider Jeffrey S. Farrow sold 2,186 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $146,462.00. Following the sale, the insider directly owned 43,316 shares in the company, valued at approximately $2,902,172. The trade was a 4.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bobak R. Azamian sold 11,964 shares of Tarsus Pharmaceuticals stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total transaction of $801,588.00. Following the completion of the sale, the chief executive officer owned 33,421 shares in the company, valued at approximately $2,239,207. This represents a 26.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,391 shares of company stock worth $5,432,035 in the last 90 days. 9.64% of the stock is owned by company insiders.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Seven Fleet Capital Management LP increased its holdings in Tarsus Pharmaceuticals by 340.0% in the 1st quarter. Seven Fleet Capital Management LP now owns 19,800 shares of the company’s stock valued at $1,389,000 after acquiring an additional 15,300 shares during the last quarter. Parallel Advisors LLC increased its holdings in Tarsus Pharmaceuticals by 139.2% in the 1st quarter. Parallel Advisors LLC now owns 500 shares of the company’s stock valued at $35,000 after acquiring an additional 291 shares during the last quarter. Bank of America Corp DE increased its holdings in Tarsus Pharmaceuticals by 57.5% in the 1st quarter. Bank of America Corp DE now owns 1,194,377 shares of the company’s stock valued at $83,786,000 after acquiring an additional 436,271 shares during the last quarter. Janus Henderson Group PLC increased its holdings in Tarsus Pharmaceuticals by 16.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,240,963 shares of the company’s stock valued at $157,223,000 after acquiring an additional 310,638 shares during the last quarter. Finally, Tri Locum Partners LP bought a new stake in Tarsus Pharmaceuticals in the 1st quarter valued at $17,719,000. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.